Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AddLife ABOSTO:ALIF B -3.58%88 ROE % is 9.16% as of Jun. 2026, which is 32% below its 10-year median of 13.57. GuruFocus rates OSTO:ALIF B with a GF Score™ of 88/100 and a GF Value™ of kr150.50 (Fairly Valued). The stock has 5 warning signs investors should review. Among 798 Medical Devices & Instruments companies, AddLife AB ranks better than 76.82% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. AddLife AB's annualized net income for the quarter that ended in Jun. 2026 was kr520 Mil. AddLife AB's average Total Stockholders Equity over the quarter that ended in Jun. 2026 was kr5,676 Mil. Therefore, AddLife AB's annualized ROE % for the quarter that ended in Jun. 2026 was 9.16%.
The historical rank and industry rank for AddLife AB's ROE % or its related term are showing as below:
OSTO:ALIF B'
s ROE % Range Over the Past 10 Years
Min: 3.83 Med: 13.57 Max: 30.92
Current: 10.93
During the past 13 years, AddLife AB's highest ROE % was 30.92%. The lowest was 3.83%. And the median was 13.57%.
OSTO:ALIF B's ROE % is ranked better than 76.82% of 798
companies
in the Medical Devices & Instruments industry
Industry Median: 2.51
vs OSTO:ALIF B: 10.93
AddLife AB (OSTO:ALIF B) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Jun. 2026) net income data. The Revenue data used here is four times the quarterly (Jun. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
AddLife AB ROE % Related Terms
AddLife AB ROE % Historical Data
* Premium members only.
The historical data trend for AddLife AB's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, AddLife AB's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AddLife AB ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AddLife AB's ROE % distribution charts can be found below:
* The bar in red indicates where AddLife AB's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
ROE % is displayed in the 30-year financial page.
AddLife AB (OSTO:ALIF B) has a ROE % of 9.16% as of Jun. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on AddLife AB and its competitors. This is 32% below median its historical median of 13.57. Over the past decade, AddLife AB's ROE % has ranged from 3.83 to 30.92. According to the industry distribution chart, AddLife AB ranks #185 out of 798 companies in the Medical Devices & Instruments industry, placing it in the top 23.2%.
Is AddLife AB's ROE % too high?
AddLife AB's current ROE % of 9.16% is 32% below median its 10-year median of 13.57. Over the past 10 years, this metric has ranged from a low of 3.83 to a high of 30.92. The Medical Devices & Instruments industry median ROE % is 2.51. AddLife AB's value of 9.16% is 264.9% above this industry median. Based on the distribution chart, AddLife AB ranks #185 out of 798 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, AddLife AB has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AddLife AB's ROE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, AddLife AB ranks #185 out of 798 companies for ROE %. This places AddLife AB in the top 23% of its industry — outperforming the majority of peers. The industry median ROE % is 2.51. AddLife AB's value of 9.16% is 264.9% above this benchmark. Historically, AddLife AB's own ROE % has ranged from 3.83 to 30.92 over the past decade. While the company's 10-year median is 13.57 vs. the industry median of 2.51, AddLife AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.51, based on 798 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AddLife AB's current ROE % of 9.16% is 264.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on AddLife AB and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AddLife AB's current ROE % is 9.16%, which is 32% below median its own 10-year median of 13.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AddLife AB stock overvalued right now?
Based on GuruFocus' analysis, AddLife AB (OSTO:ALIF B) is currently considered Fairly Valued. The stock's GF Value™ is kr150.50, compared to a current price of kr161.40 — trading 7.2% above its estimated fair value. The current ROE % is 9.16%, which is 32% below median its 10-year median of 13.57 and 264.9% above the Medical Devices & Instruments industry median of 2.51. AddLife AB's overall GF Score™ is 88/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For AddLife AB (OSTO:ALIF B), the current ROE % is 9.16% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AddLife AB (OSTO:ALIF B) Overvalued in 2026?
Based on GuruFocus' analysis, AddLife AB stock appears to be overvalued.
The current stock price of kr161.40 is trading 7.2% above its estimated GF Value™ of kr150.50.
GuruFocus considers AddLife AB to be Fairly Valued.
Key valuation signals for OSTO:ALIF B:
ROE %: 9.16% (32% below median its 10-year median of 13.57)
GF Value™: kr150.50 vs. price of kr161.40 (7.2% above fair value)
Industry Position: 264.9% above the Medical Devices & Instruments median (#185 of 798)
No single metric tells the full story. See the OSTO:ALIF B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AddLife AB is engaged in the business of providing products, services, and advisory services. The company operates in two segments: Labtech and Medtech. The Labtech segment provides analytical instruments, equipment, microscopes, consumables, and reagents, as well as software support and technical service to laboratories in medicine, research, academia and the food and pharmaceutical industries. The Medtech segment includes a range that spans from basic consumables to instruments for surgical procedures, welfare technology, and assistive devices for the elderly and disabled. The majority of revenue is derived from the Medtech segment.
88GF Score
Get the complete analysis for OSTO:ALIF B
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ALIF B has been successfully added to your 
